DCT

2:26-cv-11431

Organon LLC v. DR Reddy's Laboratories Ltd

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 2:26-cv-11431, D.N.J., 09/03/2026
  • Venue Allegations: Venue is alleged to be proper as to the foreign defendant, Dr. Reddy's Laboratories Ltd., because the court has personal jurisdiction. It is alleged to be proper as to the domestic defendant, Dr. Reddy's Laboratories, Inc., because it resides in the District of New Jersey.
  • Core Dispute: Plaintiffs allege that Defendants' proposed generic tapinarof cream, 1%-the subject of an Abbreviated New Drug Application (ANDA)-infringes twelve patents related to Plaintiffs' branded product, VTAMA.
  • Technical Context: The technology relates to topical pharmaceutical cream formulations for delivering the active ingredient tapinarof to treat inflammatory skin conditions such as plaque psoriasis and atopic dermatitis.
  • Key Procedural History: This is a Hatch-Waxman patent infringement action initiated under 35 U.S.C. § 271(e)(2) following Defendants' submission of ANDA No. 221632 to the U.S. Food and Drug Administration (FDA). The complaint states that on August 3, 2026, Defendants sent a Notice Letter with a Paragraph IV certification, asserting the patents-in-suit are invalid, unenforceable, and/or not infringed. The complaint also notes that Plaintiff Dermavant disclaimed several claims of U.S. Patent No. 11,590,088 on January 28, 2025, and that these disclaimed claims are not asserted in this action.

Case Timeline

Date Event
Early 1990s Initial development work on tapinarof begins.
2012-01-01 GlaxoSmithKline acquires rights to tapinarof.
2015-05-21 Earliest Priority Date for '160 and '743 Patents.
2018-01-01 Dermavant Sciences acquires rights to tapinarof from GlaxoSmithKline.
2019-02-05 U.S. Patent No. 10,195,160 issues.
2019-10-01 U.S. Patent No. 10,426,743 issues.
2020-05-12 U.S. Patent No. 10,647,649 issues.
2022-05-23 VTAMA receives FDA approval for topical treatment of plaque psoriasis.
2022-10-04 U.S. Patent No. 11,458,108 issues.
2022-11-15 U.S. Patent No. 11,497,718 issues.
2023-02-28 U.S. Patent No. 11,590,088 issues.
2023-03-07 U.S. Patent No. 11,597,692 issues.
2023-03-28 U.S. Patent No. 11,612,573 issues.
2023-04-04 U.S. Patent No. 11,617,724 issues.
2023-04-11 U.S. Patent No. 11,622,945 issues.
2024-01-01 Organon acquires Dermavant and rights in the VTAMA product.
2024-03-26 U.S. Patent No. 11,938,099 issues.
2024-12-12 VTAMA receives FDA approval for topical treatment of atopic dermatitis.
2025-01-28 Plaintiff Dermavant disclaims claims 1-4, 6-10, 16, 18, and 21-22 of the '088 Patent.
2026-03-10 U.S. Patent No. 12,569,453 issues.
2026-08-03 Defendants send Notice Letter regarding ANDA No. 221632.
2026-09-03 Complaint for patent infringement is filed.

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 10,195,160 - "Topical pharmaceutical compositions"

  • Patent Identification: U.S. Patent No. 10,195,160, titled "Topical pharmaceutical compositions," issued on February 5, 2019 Compl. ¶33

The Invention Explained

  • Problem Addressed: The patent addresses the challenge of creating a topical pharmaceutical composition for the active ingredient 3,5-Dihydroxy-4-isopropyl-trans-stilbene (tapinarof) that is both physically and chemically stable ʼ160 Patent, col. 1:12-18 The background notes that tapinarof is known to be sensitive to oxidation and photo degradation ʼ160 Patent, col. 1:61-63
  • The Patented Solution: The invention is a topical oil-in-water emulsion composition where the tapinarof is solubilized in the oil phase, creating a homogeneous and stable cream ʼ160 Patent, abstract The specification explains that certain oil phase components like mineral oil and petrolatum can result in non-uniform, "waxy" emulsions, whereas using an oil phase substantially free from them and comprising components like medium chain triglycerides results in a physically stable formulation (ʼ160 Patent, col. 2:9-12; '160 Patent, col. 44:41-54; '160 Patent, Fig. 2).
  • Technical Importance: This formulation provides a stable and non-irritating vehicle for delivering tapinarof into the skin to treat dermatological conditions, while minimizing systemic exposure ʼ160 Patent, col. 2:1-4

Key Claims at a Glance

  • The complaint asserts infringement of one or more claims of the ʼ160 patent Compl. ¶56 Independent claim 1 is representative and includes the following elements:
    • A topical pharmaceutical oil-in-water emulsion composition comprising:
    • 3,5-dihydroxy-4-isopropyl-trans-stilbene... in an amount of about 0.05% to about 2% by weight;
    • an oil phase comprising medium chain triglycerides... in an amount of about 2% to about 30% by weight;
    • a water phase;
    • a surfactant in an amount of about 1% to about 20% by weight, wherein the surfactant comprises at least one non-ionic emulsifying wax NF;
    • a dermatologically acceptable excipient;
    • wherein the 3,5-dihydroxy-4-isopropyl-trans-stilbene... is solubilized in the oil phase and is the only active ingredient in the oil phase;
    • wherein the oil phase is substantially free of petrolatum and mineral oil;
    • wherein the oil-in-water emulsion is homogeneous; and
    • wherein the average droplet size of the oil phase is from about 0.1 microns to about 35 microns.

U.S. Patent No. 10,426,743 - "Topical pharmaceutical compositions"

  • Patent Identification: U.S. Patent No. 10,426,743, titled "Topical pharmaceutical compositions," issued on October 1, 2019 Compl. ¶34

The Invention Explained

  • Problem Addressed: The patent, which shares its specification with the '160 Patent, addresses the challenge of creating a physically and chemically stable topical formulation for the active ingredient tapinarof ʼ743 Patent, col. 1:12-18
  • The Patented Solution: The patent claims a method of treating an inflammatory disease by administering the homogeneous topical emulsion described in the '160 Patent, where tapinarof is solubilized in an oil phase that is substantially free of petrolatum and mineral oil (ʼ743 Patent, abstract; '743 Patent, col. 4:1-19).
  • Technical Importance: This invention provides a specific method for using the stable tapinarof formulation to treat dermatological conditions like atopic dermatitis and psoriasis ʼ743 Patent, col. 4:49-51

Key Claims at a Glance

  • The complaint asserts infringement of one or more claims of the ʼ743 patent Compl. ¶63 Independent claim 1 is representative and recites a method of treatment comprising administering the composition detailed in the '160 Patent. Its essential elements are:
    • A method of treating an inflammatory disease or disorder in a patient in need thereof, the method comprising administering to said patient a topical pharmaceutical oil-in-water emulsion composition comprising:
    • [The elements of the composition are identical to those listed for claim 1 of the '160 Patent, supra].

Multi-Patent Capsule: U.S. Patent No. 10,647,649 - "Process for preparing tapinarof"

  • Patent Identification: U.S. Patent No. 10,647,649, "Process for preparing tapinarof," issued May 12, 2020 Compl. ¶35
  • Technology Synopsis: This patent describes a process for preparing tapinarof. The process claims relate to specific chemical synthesis steps for creating the active pharmaceutical ingredient.
  • Asserted Claims: The complaint asserts infringement of "one or more claims" Compl. ¶70
  • Accused Features: The complaint alleges that Defendants' "commercial manufacture" of their ANDA Product will infringe this patent Compl. ¶71

Multi-Patent Capsule: U.S. Patent No. 11,458,108 - "Topical pharmaceutical compositions"

  • Patent Identification: U.S. Patent No. 11,458,108, "Topical pharmaceutical compositions," issued October 4, 2022 Compl. ¶36
  • Technology Synopsis: The patent, which shares its specification with the lead patents, claims a topical emulsion composition for tapinarof that is stable and effective for skin delivery. The claims focus on the composition being a cream that is homogenous and has a specific average droplet size.
  • Asserted Claims: The complaint asserts infringement of "one or more claims" Compl. ¶77
  • Accused Features: The complaint alleges DRL's ANDA Product is a topical cream that, to be bioequivalent to VTAMA, must have the same physicochemical and structural attributes, thereby infringing the composition claims (Compl. ¶52; Compl. ¶53).

Multi-Patent Capsule: U.S. Patent No. 11,497,718 - "Use of tapinarof for the treatment of atopic dermatitis"

  • Patent Identification: U.S. Patent No. 11,497,718, "Use of tapinarof for the treatment of atopic dermatitis," issued November 15, 2022 Compl. ¶37
  • Technology Synopsis: This patent claims methods of treating atopic dermatitis by topically administering a tapinarof composition. The claims are directed to achieving specific clinical outcomes, such as an improvement in the Investigator Global Assessment (IGA) score.
  • Asserted Claims: The complaint asserts infringement of "one or more claims" Compl. ¶84
  • Accused Features: The complaint alleges inducement of infringement because the label for DRL's ANDA Product will be a copy of the VTAMA label and will instruct patients and practitioners on the infringing use for treating atopic dermatitis Compl. ¶54 Compl. ¶85

(Analysis would continue in this capsule format for the remaining seven patents-in-suit: '088, '692, '573, '724, '945, '099, and '453, covering additional composition claims, process claims, and method of use claims for psoriasis and atopic dermatitis.)

III. The Accused Instrumentality

Product Identification

  • The accused instrumentality is Defendants' ("DRL's") ANDA Product, identified as a generic version of Organon's VTAMA tapinarof cream, 1%, for which DRL is seeking FDA approval via ANDA No. 221632 Compl. ¶1

Functionality and Market Context

  • The complaint alleges that DRL's ANDA Product is a topical cream for the treatment of plaque psoriasis and will be bioequivalent to VTAMA Compl. ¶¶52-53 To achieve bioequivalence for a topical formulation, the complaint alleges a generic must typically demonstrate no significant difference in active or inactive ingredients and possess the same physicochemical and structural attributes as the reference drug Compl. ¶53 The complaint further alleges that DRL's product will be sold with a label that is a copy of VTAMA's label, which authorizes its use for treating plaque psoriasis and atopic dermatitis Compl. ¶27 Compl. ¶54

IV. Analysis of Infringement Allegations

The complaint's infringement theory is predicated on the requirements of the Hatch-Waxman Act. It alleges that for DRL's ANDA Product to be approved by the FDA as a generic substitute for VTAMA, it must necessarily have the same active ingredient, strength, dosage form, and be bioequivalent, which Plaintiffs allege requires it to have the same formulation characteristics claimed in the composition patents Compl. ¶¶50-53 For method-of-use patents, the theory is that DRL will induce infringement by providing a label that copies VTAMA's and instructs users on the patented methods Compl. ¶54

No probative visual evidence provided in complaint.

'160 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A topical pharmaceutical oil-in-water emulsion composition comprising: 3,5-dihydroxy-4-isopropyl-trans-stilbene...in an amount of about 0.05% to about 2% by weight... DRL's ANDA Product is alleged to have the same active ingredient and strength as VTAMA, which is 1% tapinarof cream. ¶50 col. 10:20-25
an oil phase comprising medium chain triglycerides... DRL has represented to the FDA that its formulation is bioequivalent to VTAMA, which Plaintiffs allege requires it to have the same physicochemical and structural attributes, including the same oil phase components. ¶53 col. 11:1-15
wherein the 3,5-dihydroxy-4-isopropyl-trans-stilbene...is solubilized in the oil phase... It is alleged that to be bioequivalent, DRL's product must have the same attributes as the reference drug, which requires the active ingredient to be solubilized in the oil phase. ¶53 col. 8:26-34
wherein the oil phase is substantially free of petrolatum and mineral oil... The complaint alleges that DRL's product is designed to copy the VTAMA formulation, which is asserted to be substantially free of petrolatum and mineral oil. ¶52 col. 5:4-7
wherein the oil-in-water emulsion is homogeneous; and wherein the average droplet size of the oil phase is from about 0.1 microns to about 35 microns. It is alleged that for DRL's product to be bioequivalent, it must exhibit the same physicochemical attributes, including being a homogeneous emulsion with a comparable droplet size. ¶53 col. 4:32-35

'743 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A method of treating an inflammatory disease or disorder...comprising administering to said patient a topical pharmaceutical oil-in-water emulsion composition comprising... DRL will encourage and induce infringement by marketing its ANDA Product with a label that is a copy of VTAMA's label, which provides instructions for treating atopic dermatitis. ¶54; ¶64 col. 4:49-51
[Composition elements identical to '160 Patent Claim 1, supra] DRL's ANDA Product is alleged to be a bioequivalent copy of the VTAMA formulation, thereby meeting the compositional limitations of the claim. ¶53 col. 10:20-25
  • Identified Points of Contention:
    • Scope Questions: A central dispute will likely involve the construction of "substantially free of petrolatum and mineral oil." The specification provides some quantitative guidance (e.g., ≤3%, ≤2%, or ≤1%), which may become a focal point for non-infringement arguments if DRL's formulation includes any amount of these excipients ('160 Patent, col. 5:5-7).
    • Technical Questions: A key question for the court will be whether demonstrating "bioequivalence" for FDA purposes legally and factually necessitates infringement of the composition claims. Plaintiffs allege this is the case Compl. ¶53, while DRL's Paragraph IV certification necessarily takes the opposite position Compl. ¶49 The analysis will turn on whether DRL's formulation is technically identical or merely an equivalent for regulatory purposes that has been designed to avoid the specific claim limitations.

V. Key Claim Terms for Construction

  • The Term: "homogeneous"

    • Context and Importance: This term is critical because the patents distinguish the invention from prior art that resulted in "non-uniform" emulsions with "wax-like material" ('160 Patent, col. 43:18-22; '160 Patent, Fig. 1). Practitioners may focus on this term because infringement will depend on whether DRL's product meets this standard of uniformity, a potentially fact-intensive inquiry.
    • Intrinsic Evidence for Interpretation:
      • Evidence for a Broader Interpretation: The term itself is broad, and a party might argue it simply means a uniform mixture without visible phase separation to the naked eye.
      • Evidence for a Narrower Interpretation: The specification provides a specific definition: "a uniform dispersal of one phase within the other" ('160 Patent, col. 38:41-43). The patent also provides a visual counterexample in Figure 1, showing "waxy regions" in a non-homogeneous formulation, which could be used to argue for a specific microscopic standard of homogeneity ('160 Patent, Fig. 1).

  • The Term: "solubilized in the oil phase"

    • Context and Importance: The claims require the active ingredient to be "solubilized in the oil phase." Practitioners may focus on this term because the degree of solubilization required for infringement is a potential point of dispute, especially if DRL's formulation achieves bioequivalence with a different mechanism or degree of solubilization.
    • Intrinsic Evidence for Interpretation:
      • Evidence for a Broader Interpretation: A party could argue the term simply requires the active ingredient to be dissolved primarily in the oil phase, without requiring 100% solubilization.
      • Evidence for a Narrower Interpretation: The specification provides quantitative context, stating that in certain embodiments, "≥95% or ≥98% w/w of the active ingredient is solubilized in the oil phase" ('160 Patent, col. 8:30-34). This language could support an argument that the claim requires a very high, near-complete level of solubilization in the oil phase.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges induced and contributory infringement for all asserted patents. For the method-of-use patents (e.g., '718, '088), inducement is based on the allegation that DRL will copy VTAMA's label, which will instruct and encourage doctors and patients to perform the patented methods of treatment Compl. ¶54 Compl. ¶66 For the composition patents (e.g., '160, '108), contributory infringement is based on the allegation that DRL's product is a material component especially made for infringing use and not suitable for substantial non-infringing use Compl. ¶60 Compl. ¶81
  • Willful Infringement: The complaint does not explicitly plead "willful infringement." However, it alleges that DRL has had knowledge of the patents-in-suit since at least the date of its ANDA submission, citing the patents' listing in the FDA's Orange Book and DRL's August 3, 2026, Notice Letter Compl. ¶58 Compl. ¶65 The prayer for relief asks for a finding that this is an "exceptional case" and an award of attorney's fees, which is the statutory relief associated with such conduct Compl., Prayer for Relief ¶cc

VII. Analyst's Conclusion: Key Questions for the Case

  • A core issue will be one of bioequivalence versus infringement: does DRL's ANDA Product achieve bioequivalence for FDA purposes by creating a formulation that is identical to the one claimed in the patents-in-suit, or has it been designed around the claims in a way that is functionally equivalent for regulatory purposes but technically distinct for infringement purposes? The resolution will depend on the specific composition of DRL's product, which is not yet public.
  • A second key question will be one of definitional scope: how will the court construe terms like "homogeneous" and "substantially free of petrolatum"? The patents provide specific examples and quantitative metrics that will be central to this analysis, raising the question of whether DRL's formulation falls inside or outside these defined boundaries.
  • A final issue will be one of induced infringement: for the method-of-use patents, the dispute will likely center on whether DRL's product label, by copying the VTAMA label, provides sufficient instruction and encouragement to doctors and patients to perform the patented methods of treatment, thereby establishing the requisite intent for inducement.